Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU 86017

Drug Development Research

Volumn 39, Issue 2, 1996, Pages 138-146

  Dai, De Zai ^a   Yu, Feng ^a   Li, Hai Tao ^a   Tang, Yi Qun ^a   An, Lu Fan ^a   Huang, Wen Long ^a   Peng, Si Xun ^a   Hao, Xue Mei ^b   Zhou, Bei Ai ^b   Hu, Chai Hong ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Class III antiarrhythmic agent; CPU 86017; Ion channels; Patch clamp

Indexed keywords

ANTIARRHYTHMIC AGENT; CPU 86017; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANOXIA; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; GUINEA PIG; HEART; HEART PAPILLARY MUSCLE; HEART RHYTHM; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE ACTION POTENTIAL; MUSCLE CELL; NONHUMAN; PACEMAKER; PATCH CLAMP; RABBIT; RAT;

EID: 0030437565     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2299(199610)39:2<138::aid-ddr5>3.0.co;2-q     Document Type: Article

References (46)

1. Bashir Y, Thomsen PB, Kingma JX, Moller M, Wong G, Cobbe Sh, Joraens L, Campbell RWF, Rasmussen HS, Camm AJ (the Dofeltilide arrhythmia study group) (1995): Electrophysiologic profile and efficacy of intravenous Dofetilide (UK 68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 76:1040-1044.
2. Chang KC, Park CO, Hong SG (1994): Effects of GS 386, a novel dihydroisoquinidine compound, on rabbit atrial myocytes and rat aorta. Drug Dev Res 33:454-459.
3. 2+-ATPase activity induced by 1-thyroxine in rats. Chin J Pharmacol Toxicol 9:228-230.
4. +-ATPase activity induced by 1-thyroxine in rats. Chin J Pharmacol Toxicol 9:265-267.
5. Colatsky TJ, Argentieri TM (1994): Potassium channel blockers as antiarrhythmic drugs. Drug Dev Res 33:235-249.
6. Colatsky TN (1995): Antiarrhythmic drugs: Where are we going? Pharmaceut News 2:17-23.
7. Cook NS (1988): The pharmacology of potassium channels and their therapeutic potential. TIPS 9:21-27.
8. Dai DZ (1989): The new idea and strategy of developing antiarrhythmic drugs. Adv Pharmaceut Sci 13:4-9.
9. Dai DZ, Zong JG, Lei NY, Bai MQ, Rong P (1995): Changes of super-oxide dismutase, malondialdehyde, creatine phosphokinase in non-infarcted of an infarcted heart in rats and responded to drug treatment. J Chin Pharmaceut Univ 26:291-296.
10. Echt DS, Leibson PR, Mitchell LB, and the CAST Investigators (1991): Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmias Suppression Trial. N Engl J Med .324:181-788.
11. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ, Baskin EP, Lynch JJ, Salata JJ (1995): Use-dependent effects of the Class III antiarrhythmic agent NE-10064 (Azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26:259-271.
12. Fruman H, Kerin NZ, Rubenfire 14 (1989): Classification of antiarrhythmic drugs. J Clin Pharmacol 29:387-394.
13. Gill JW, Heel RC, Fitton A (1992): Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43:69-110.
14. Goldstein S (1989): Mechanisms and prevention of sudden death in coronary heart disease. J Clin Pharmacol 29:413-417.
15. Gout B, Nichols AJ, Feuerstein GZ, Bril A (1995): Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia. J Cardiovasc Pharmacol 26:636-644.
16. Groh WJ, Gibson KJ, McAnulty JL, Maylie JG (1995): Beta-adrenergic blocking property of dl-sotalol maintains Class III efficacy in guinea pig ventricular muscle after isopreterenol. Circulation 91:262-264.
17. ATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 26:145-152.
18. Gulker t Spyra W, Thale J, Krisphove F, Hubner A, Bender F (1987): Assessment of the electrophysiologic, antiarrhythmic, and haemodynamic profile of a new isoquinidine derivative. Arzneimitelforschung/Drug Res 37:917-920.
19. Guo ZB, Cao WY, Xu Z, Qing L (1991): Electrophysiological effects of berbamine on ischemic ventricular tachyarrhythmia. Act Pharmacol Sin 12:44-47.
20. Hou DH, Li L, Wang QJ, Chen GF (1983): The comparative studies on the antihypoxic and antiarrhythmic effects of five protoberberine compounds. J Nanjing Coll Pharmacy No: 1 (Total No: 21):30-33.
21. Hua Z, Wang XL (1994): Suppressing effect by berberine on potassium ion channels in guinea pig ventricular myocytes. Act Pharmacol Sin 29:578-580.
22. Ijzerman AP, Soudijn W (1989): The antiarrhythmic properties of beta-adrenoceptor antagonists. TIPS 10:31-36.
23. Kurz T, Offner B, Schreieck I, Richardt G, Tolg R, Schomig A (1995): Nonexocytotic noradrenaline release and ventricular fibrillation in ischemic rat hearts. Naunyn Schmiedebergs Arch Pharmacol 352:491-496.
24. Miyachi EI, Manoach M, Uchiyama H, Watanabe Y (1995): Is cyclic AMP involved in the defibrillatory effect of sotalol? Life Sci 26:393-399.
25. Nakaya, Tohse N, Takeda Y, Kanno M (1993): Effects of MS-551, a new Class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 109:157-163.
26. Polikar R, Burger AG, Scherrer U, Nicod P (1993): The thyroid and the heart. Circulation 87:1435-1441.
27. Poyser RH, Hamilton TC (1994): Potassium channel modulators: Current situation and future expectations. Drug Fut 19:39-47.
28. Rong P, Dai DZ, Zhang JE (1992): Global depletion of myocardial norepinephrine and ATP after left coronary artery occlusion in rats. Act Pharmacol Sin 13:333-337.
29. + current. J Gen Physiol 96:195-215.
30. Silverman HS, Stern MD (1994): Ionic basis of ischemic cardiac injury: Insights for cellular studies. Cardiovasc Res 28:581-597.
31. Stevensen WG, Weiss JN, Wiener I, Nademanee K (1989): Slow conduction in the infarct scar: Relevance to the occurrence, detection and ablation of ventricular reentry circuits resulting from myocardial infarction. Am Heart J 117:452-467.
32. Sun A-Y, Li SX (1993): Antifibrillatory effect of tetrahydroberberine. Act Pharmacol Sin 14:301-305.
33. Tamargo JJ, Perez O, Deipon E, Garcia-Rafanell J, Gamez L, Cavalcani F (1995): Cardiovascular effects on the novel potassium channel opener UR-8255. J Cardiovasc Pharmacol 26:295-305.
34. K blocking drug, UK-68,798; potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 16:401-410.
35. Triggle DJ (1994): Ion channels and diseases. Drug Dev Res 33:364-372.
36. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 69:623-637.
37. Wang Y, Li DX (1987): Anti-arrhythmic action of 1-tetrahydropalmatine. Acta Pharmacol Sin 8:337-340.
38. Wang YX, Zheng YO, Tan YE (1993): Protective effect of d, 1-tetrahydroplamatine on cardiac arrhythmias induced by reperfusion of ischemic myocardium. Chin Pharmacol Bull 9:358-361.
39. Wellens LTJ, Brugada P, Farre J (1984): Ventricular arrhythmias: Mechanisms and actions of antiarrhythmic drugs. Am Heart J 107:1053-1057.
40. Wible BA, Brown AM (1994): Function and structure of voltage-dependent potassium channels. Drug Dev Res 33:225-234.
41. Xu Z, Cao H-Y, Li Q (1989): Protective effect of berberine on spontaneous ventricular fibrillation in dogs after myocardial infarction. Act Pharmacol Sin 10:320-324.
42. Yao WX, Xia GJ, Zenq WZ, Jiang MAPD (1990): Effects of benzyltetrahydropalmatine on delayed after depolarization and triggered activity and rabbit His-bundle electrogram. Act Pharmacol Sin 11:141-143.
43. Yu SQ, Dai DZ, Chu YW (1991): Subdividing the infarcted rat heart into the infarcted zone, risk zone and non-infarcted zone by fluorescence potency after intravenous tetracycline. J Chin Pharmaceut Univ 22:213-217.
44. Zamponi GW, Duff HJ, French RJ, Sheldon RS (1994): Biochemical and biophysical studies of the interaction of Class I antiarrhythmic drugs with the cardiac sodium channel. Drug Dev Res 33:277-294.
45. Zhang QY, He GY, Wu XD (1991): Antiarrhythmic effects of tetrahydroberberine. Chin Pharmacol Bull 7:459-462.
46. Zhao DHP, Zhao GD, Shang BH (1988): The experimental antiarrhythmic effects of 1-stepholidine. Chin Pharmacol Bull 4:35-38.